<DOC>
	<DOC>NCT00307801</DOC>
	<brief_summary>The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.</brief_summary>
	<brief_title>Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Women 18 years or older And with a diagnosis of dysfunctional uterine bleeding without organic pathology And with at least one of the following symptoms: prolonged, frequent or excessive bleeding. The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study. Women with a history of endometrial ablation or dilatation and curettage within 2 months prior to study start will be excluded.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Dysfunctional uterine bleeding</keyword>
</DOC>